and now report on 710 African-Americans (AAs) (461 cases, 249 controls) and 454 European Americans (EAs) (140 cases, 126 controls) for a total of 1164 new subjects. These subjects have been combined with the 1608 original EA subjects recruited from COGEND. The Australian subjects are not retained because there are significant differences in recruitment, ages and gender distributions in that cohort. The entire U.S.-based COGEND sample size is 2772 subjects and Table 1 gives demographics (cases/controls, sex, age) for the sample. When reporting results for the EA groupings, we use “original” and “new” to specify those two subsamples, and “all EAs” or “EAs” to indicate the complete EA sample. The full sample of all EAs and AAs combined (N=2772) is denoted by “full sample.” This full U.S. sample was recently analyzed for SNPs in the CHRNA5-CHRNA3-CHRNB4 region (Saccone et al., 2009b); here, we extend the study of this sample to SNPs in other nicotinic receptors.
